ALVR / AlloVir (ALVR) Up on Third RMAT Status From FDA for Posoleucel

AlloVir stock fell today given concerns over potential selling pressure from a recent lock-up expiration. The lock-up agreement was related to a new s more_horizontal

Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include Crocs (CROX), AlloVir (ALVR), Arcadia Biosciences (RK more_horizontal

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Planet Fitness (PLNT), AlloVir (ALVR), Entergy more_horizontal

In recent Securities & Exchange Commission filings, Gilead Sciences Inc. NASDAQ: GILD revealed that it had purchased significant stakes in AlloVir Inc more_horizontal

Gilead has purchased $10.9 million in shares of Allovir, a biotech company specializing in cell therapy and organ transplant, giving it a 15% ownershi more_horizontal

Positive final results from the phase 2 study, using posoleucel for BK Virus, were presented at the American Transplant Congress 2023. Discussions wit more_horizontal

AlloVir, Inc. (ALVR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). more_horizontal

AlloVir stock fell to a 52-week low on Thursday. The company's lead therapy has begun phase 3 trials to treat kidney transplant patients who had virus more_horizontal